Mafoprazine
Veterinary antipsychotic
From Wikipedia, the free encyclopedia
Mafoprazine is an antipsychotic of the phenylpiperazine class which is used in veterinary medicine.[1] Intramuscular injections of mafoprazine mesylate are used for the sedation of pigs either on its own,[2] or in combination with sodium pentobarbital[3] or thiopental.[4]
| Clinical data | |
|---|---|
| Trade names | Mafropan |
| AHFS/Drugs.com | Monograph |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H28FN3O3 |
| Molar mass | 401.482 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
It demonstrates activity as a D2 dopamine receptor antagonist, an α1 adrenergic receptor antagonist, and an α2 adrenergic receptor agonist.[5]
The affinity of mafoprazine for D2 dopamine receptors is 6 and 16 times lower than that of chlorpromazine and haloperidol, respectively, but 2 times higher than that of azaperone.[5]
The Ki for various receptors was determined using rat neuronal receptor binding assays.[citation needed]
History
Mafoprazine was first synthesized in 1988.[5] It is sold as Mafropan® by DS Pharma Animal Health Co. Ltd., Osaka, Japan.